ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3137

Assessing System-Level Performance Measures for Early Rheumatoid Arthritis in a Large Multicenter Cross-Country Prospective 8-Year Observational Cohort Study

Claire E H Barber1, Cheryl Barnabe2, Glen Hazlewood2, Orit Schieir3, Lyne Nadeau4, J Carter Thorne5, Vandana Ahluwalia6, Susan J. Bartlett7, Gilles Boire8, Boulos Haraoui9, Carol Hitchon10, Edward Keystone11, Diane Tin12, Janet E. Pope13, Lisa Denning14, Vivian P. Bykerk15 and Canadian early Arthritis Cohort (CATCH) Investigators, 1University of Calgary, Calgary, AB, Canada, 2Division of Rheumatology, University of Calgary, Calgary, AB, Canada, 3Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, 4McGill University, Qubec, QC, Canada, 5Southlake Regional Health Centre, Newmarket, ON, Canada, 6Ontario Rheumatology Association, Brampton, ON, Canada, 7Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 8Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, 9Institute de Rheumatologie, Montreal, QC, Canada, 10University of Manitoba, Winnipeg, MB, Canada, 11Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, 12The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 13University of Western Ontario, St Joseph's Health Care, London, ON, Canada, 14William Osler Health System, Brampton, ON, Canada, 15Divison of Rheumatology, Hospital for Special Surgery, New York, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Quality Indicators and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, November 16, 2016

Title: Quality Measures and Quality of Care II

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: The Arthritis Alliance developed a set of 6 performance measures to evaluate timely access to care and treatment for inflammatory arthritis. A national study is currently underway to test these measures in different data sources. The objective of this study was to examine 3 of these measures in early rheumatoid arthritis (ERA) patients receiving usual care in rheumatology clinics participating in a national longitudinal early arthritis study.

Methods: This study included ERA patients enrolled between January 1st 2007-January 31st 2015 who met 1987 or 2010 ACR/EULAR RA criteria and had < 1 year of symptom duration at cohort entry. Patients who died or moved away within 1 year of the baseline visit or who had <1 year of follow-up were excluded. Each measure was computed annually. Measures included: i) percentage of patients with RA seen in yearly follow-up (operationalized at fixed 12 and 14 month windows from the patient’s baseline visit), ii) annual percentage of RA patients treated with a disease-modifying drug (DMARD, calculated as the proportion of patients with RA with at least one record of DMARD or biologic use) and, iii) time from new RA diagnosis to initiation of DMARD therapy (defined by the time between the date of diagnosis of RA to the date of first starting a DMARD and reported as 50th and 90th percentile times as well as the percentage prescribed DMARDs within 2 weeks of diagnosis).

Results: 1927 RA patients were included. The mean age of the cohort was 54, with 73% female and 82% Caucasian. The average disease duration was 5.8 months and the mean DAS28 was 5.1 at baseline. Over 8 years 72% of patients were seen in yearly follow-up; when using a 14-month window this increased to 76%. The yearly percentage of newly diagnosed RA patients on a DMARD ranged between 92-100%; however, considering the whole cohort overtime the total proportion on DMARDs declined from 94% in 2007 to 70% in 2015. Between 2007 and 2015 the percentage of RA patients who received DMARD treatment within 14 days of diagnosis increased from 74% to 90%. Median time to DMARD therapy was 0 days (50th percentile) during all years of measurement indicating treatment occurred at time of diagnosis; and the 90th percentile decreased from 89 to 6 days between 2007 and 2015.

Conclusion: Between 2007-2015 the percentage meeting benchmarks for time to DMARD therapy increased in CATCH from 74% to 90%. A drop-off in yearly follow-up is typical of many observational studies though less in this study, perhaps due to benefits of universal access to care. This may not necessarily reflect a gap in care as patients may have returned to usual follow-up with the rheumatologist. The decline in percentage on DMARD over time likely represents a number of factors including: DMARD-free remission associated with earlier diagnosis and treatment, patient engagement and non-adherence and a possible care gap. Analysis of medication use over time is an ongoing goal of this study. This study represents a best-case scenario for capturing performance measures from systematically collected data demonstrating the feasibility of rapid DMARD initiation. Our findings may be useful as a benchmark while testing the measures using other settings and data sources.


Disclosure: C. E. H. Barber, None; C. Barnabe, None; G. Hazlewood, None; O. Schieir, None; L. Nadeau, None; J. C. Thorne, abbvie, 5,Amgen, 5,AstraZeneca, 5,Bristol-Myers Squibb, 5,Centocor, Inc., 5,Celgene, 5,Genzyme Corporation, 5,hospira, 5,Pfizer Inc, 5,Roche Pharmaceuticals, 5,Genzyme Corporation, 8,Medac Pharma, 8,Antares, 8,Abbvie, 2,Amgen, 2,AstraZeneca, 2,Celgene, 2,Eli Lilly and Company, 2,Novartis Pharmaceutical Corporation, 2,Pfizer Inc, 2; V. Ahluwalia, None; S. J. Bartlett, None; G. Boire, None; B. Haraoui, Abbvie, 5,Amgen, 5,Bristol-Myers Squibb, 5,Celgene, 5,Eli Lilly and Company, 5,Janssen Pharmaceutica Product, L.P., 5,Merck Pharmaceuticals, 5,Pfizer Inc, 5,Roche Pharmaceuticals, 5,UCB, 5; C. Hitchon, None; E. Keystone, Abbott, Amgen, AstraZeneca, BMS, Hoffman-LaRoche, Janssen, Eli Lilly and Company, Novartis, Pfizer, Sanofi-Aventis, UCB, 2,Abbott, AstraZeneca, Biotest, BMS, Crescendo, Hoffmann-LaRoche, Genentech, Janssen, Eli Lilly and Company, Merck, Pfizer, UCB, 5,Abbott, AstraZeneca, BMS Canada, Hoffmann-LaRoche, Janssen, Pfizer, UCB, Amgen, 9; D. Tin, None; J. E. Pope, Abbvie, 5,Actelion Pharmaceuticals US, 5,Amgen, 5,Bayer, 5,Bristol-Myers Squibb, 5,Genzyme Corporation, 5,Hospira, 5,Eli Lilly and Company, 5,Merck Pharmaceuticals, 5,Novartis Pharmaceutical Corporation, 5,Pfizer Inc, 5,Regeneron, 5,Roche Pharmaceuticals, 5,Sanofi-Aventis Pharmaceutical, 5,UCB, 5,Amgen, 2,Bristol-Myers Squibb, 2,Pfizer Inc, 2,Roche Pharmaceuticals, 2,UCB, 2; L. Denning, None; V. P. Bykerk, AbbVie, Bristol-Myers Squibb, Pfizer, Roche/Genentech, Regeneron, and UCB Pharma, 5.

To cite this abstract in AMA style:

Barber CEH, Barnabe C, Hazlewood G, Schieir O, Nadeau L, Thorne JC, Ahluwalia V, Bartlett SJ, Boire G, Haraoui B, Hitchon C, Keystone E, Tin D, Pope JE, Denning L, Bykerk VP. Assessing System-Level Performance Measures for Early Rheumatoid Arthritis in a Large Multicenter Cross-Country Prospective 8-Year Observational Cohort Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/assessing-system-level-performance-measures-for-early-rheumatoid-arthritis-in-a-large-multicenter-cross-country-prospective-8-year-observational-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessing-system-level-performance-measures-for-early-rheumatoid-arthritis-in-a-large-multicenter-cross-country-prospective-8-year-observational-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology